Navigation Links
Watson Files FDA Application for Generic Mucinex(R) D
Date:6/10/2009

- Paragraph IV Litigation Underway -

CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin pseudoephedrine HCI extended-release 600mg/60mg and 1200mg/120mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc. Watson Laboratories, Inc. - Florida's guaifenesin pseudoephedrine HCI extended-release tablet products are the generic versions of Reckitt Benckiser Inc.'s Mucinex(R) D product, which are indicated to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. Watson Laboratories, Inc. - Florida previously filed ANDAs seeking approval to market generic versions of Reckitt Benckiser Inc.'s Mucinex(R) and Mucinex(R) DM products.

Reckitt Benckiser filed suit against Watson Pharmaceuticals, Inc. and Watson Laboratories, Inc. - Florida on June 5, 2009 in the U.S. District Court for the Southern District of Florida seeking to prevent Watson from commercializing its products prior to expiration of U.S. patent numbers 6,372,252 and 6,955,821. Reckitt Benckiser's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson Laboratories, Inc. - Florida's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner. Based on available information, Watson Pharmaceuticals, Inc. believes that Watson Laboratories, Inc. - Florida may be the first applicant to file an ANDA for a generic version of Mucinex(R) D and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

For the twelve-months ended March 31, 2009, Mucinex(R) D products had total U.S. sales of approximately $62 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Mucinex(R) D is a registered trademark of Reckitt Benckiser Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
2. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
3. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
4. Watson Files FDA Applications for Generic Mucinex(R)
5. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
6. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
7. Mark G. Watson Named Executive Director of Radiological Society of North America
8. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
9. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
10. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
11. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... N.J. (PRWEB) , ... January 18, 2017 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... will be presenting at the upcoming WCBP Conference, to be held at the ...
(Date:1/18/2017)... Lebanon, NH (PRWEB) , ... January 18, 2017 ... ... the launch of the revolutionary Active Brake Technology (ABT), an innovative braking system ... stability. , Active Brake Technology addresses one of the biggest concerns of beginner ...
(Date:1/17/2017)... Marne, Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking ... those who choose to lurk in the corners and commit the crime of stalking, a ... drug use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: ...
(Date:1/17/2017)... Angeles, California (PRWEB) , ... January 17, 2017 ... ... to have a point of difference. Eden Activewear is a stand-out company for ... Eden are exclusively online and only manufacture on demand, this is called 'Agile' ...
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful Balance announces ... company, owned and operated by Ed Stroup, was created to offer the highest ... highest level of customer service. Healthful Balance products can be purchased online through ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... LONDON , January 18, 2017 ... community to share research resources, has opened its first North ... . ... This marks an expansion for Ximbio following its launch in ... Cancer Research Technology (CRT), the commercialization arm of the foundation ...
(Date:1/18/2017)... China,s National Regulatory Authority Chinese Food and Drug ... Dynavax Flanders Institute Food and Drug Administration ... Gavi Alliance Glaxo Smith Klein ... Service Bureau, Japan Immune Targeting Systems ... Jenner Institute, University of oxford Johnson & Johnson ...
(Date:1/17/2017)... 2017 EU5 Glucose Monitoring Market Outlook to ... Glucose Monitoring Market Outlook to 2022", provides key market ... provides value, in millions of US dollars, volume (in ... Blood Glucose Meters, Blood Glucose Test Strips and Lancets. ... shares data for each of these market segements, and ...
Breaking Medicine Technology: